Stem definition | Drug id | CAS RN |
---|---|---|
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) receptors | 5091 | 706808-37-9 |
Molecule | Description |
---|---|
Synonyms:
|
Belatacept, a selective T-cell (lymphocyte) costimulation blocker, binds to CD80 and CD86 on antigen-presenting cells thereby blocking CD28 mediated costimulation of T lymphocytes. In vitro, belatacept inhibits T lymphocyte proliferation and the production of the cytokines interleukin-2, interferon-gamma, interleukin-4, and TNF-alfa. Activated T lymphocytes are the predominant mediators of immunologic rejection
|
Dose | Unit | Route |
---|---|---|
12.50 | mg | P |
None
Date | Agency | Company | Orphan |
---|---|---|---|
June 17, 2011 | EMA | ||
June 15, 2011 | FDA | BRISTOL MYERS SQUIBB |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Kidney transplant rejection | 199.80 | 46.08 | 41 | 1448 | 3946 | 50599689 |
Transplant rejection | 153.94 | 46.08 | 39 | 1450 | 9570 | 50594065 |
Graft loss | 108.72 | 46.08 | 17 | 1472 | 340 | 50603295 |
Cytomegalovirus infection | 100.17 | 46.08 | 32 | 1457 | 17930 | 50585705 |
Thrombotic microangiopathy | 71.74 | 46.08 | 21 | 1468 | 8770 | 50594865 |
Eye infection toxoplasmal | 61.06 | 46.08 | 10 | 1479 | 270 | 50603365 |
Cytomegalovirus gastrointestinal infection | 60.57 | 46.08 | 10 | 1479 | 284 | 50603351 |
Tonsil cancer | 56.42 | 46.08 | 9 | 1480 | 205 | 50603430 |
Polyomavirus viraemia | 55.97 | 46.08 | 10 | 1479 | 456 | 50603179 |
Haemolytic uraemic syndrome | 55.37 | 46.08 | 13 | 1476 | 2306 | 50601329 |
Herpes simplex meningitis | 52.29 | 46.08 | 7 | 1482 | 43 | 50603592 |
Intentional product use issue | 50.06 | 46.08 | 30 | 1459 | 76888 | 50526747 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Kidney transplant rejection | 303.13 | 37.36 | 75 | 2022 | 6930 | 29565500 |
Transplant rejection | 172.51 | 37.36 | 51 | 2046 | 9161 | 29563269 |
Graft loss | 90.51 | 37.36 | 19 | 2078 | 829 | 29571601 |
Post transplant lymphoproliferative disorder | 75.43 | 37.36 | 24 | 2073 | 5469 | 29566961 |
Cytomegalovirus infection | 73.91 | 37.36 | 35 | 2062 | 23180 | 29549250 |
COVID-19 | 70.19 | 37.36 | 39 | 2058 | 35975 | 29536455 |
BK virus infection | 58.21 | 37.36 | 19 | 2078 | 4688 | 29567742 |
Thrombotic microangiopathy | 57.40 | 37.36 | 22 | 2075 | 8659 | 29563771 |
Retinal artery occlusion | 43.91 | 37.36 | 12 | 2085 | 1611 | 29570819 |
Off label use | 40.06 | 37.36 | 74 | 2023 | 300726 | 29271704 |
Progressive multifocal leukoencephalopathy | 40.02 | 37.36 | 17 | 2080 | 8702 | 29563728 |
Skin papilloma | 38.49 | 37.36 | 11 | 2086 | 1738 | 29570692 |
Brain abscess | 38.08 | 37.36 | 12 | 2085 | 2643 | 29569787 |
Epstein-Barr virus infection | 37.47 | 37.36 | 15 | 2082 | 6614 | 29565816 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Kidney transplant rejection | 422.56 | 34.56 | 97 | 3070 | 9414 | 64486151 |
Transplant rejection | 235.60 | 34.56 | 69 | 3098 | 17332 | 64478233 |
Graft loss | 168.87 | 34.56 | 31 | 3136 | 976 | 64494589 |
Cytomegalovirus infection | 162.49 | 34.56 | 63 | 3104 | 37136 | 64458429 |
Thrombotic microangiopathy | 108.91 | 34.56 | 38 | 3129 | 16617 | 64478948 |
Pneumocystis jirovecii pneumonia | 100.35 | 34.56 | 41 | 3126 | 27593 | 64467972 |
COVID-19 | 96.58 | 34.56 | 52 | 3115 | 65088 | 64430477 |
Post transplant lymphoproliferative disorder | 83.03 | 34.56 | 27 | 3140 | 9517 | 64486048 |
BK virus infection | 68.68 | 34.56 | 22 | 3145 | 7390 | 64488175 |
Progressive multifocal leukoencephalopathy | 65.98 | 34.56 | 27 | 3140 | 18205 | 64477360 |
Off label use | 59.85 | 34.56 | 109 | 3058 | 632697 | 63862868 |
Eye infection toxoplasmal | 56.49 | 34.56 | 11 | 3156 | 476 | 64495089 |
Cytomegalovirus colitis | 54.93 | 34.56 | 16 | 3151 | 3912 | 64491653 |
Respiratory failure | 54.12 | 34.56 | 52 | 3115 | 161131 | 64334434 |
Cytomegalovirus gastrointestinal infection | 51.06 | 34.56 | 10 | 3157 | 446 | 64495119 |
Herpes simplex meningitis | 48.03 | 34.56 | 7 | 3160 | 48 | 64495517 |
Cytomegalovirus viraemia | 45.98 | 34.56 | 18 | 3149 | 10810 | 64484755 |
Haemolytic uraemic syndrome | 45.89 | 34.56 | 14 | 3153 | 4007 | 64491558 |
Cervicitis | 45.72 | 34.56 | 8 | 3159 | 190 | 64495375 |
Acute kidney injury | 44.36 | 34.56 | 79 | 3088 | 449161 | 64046404 |
Polyomavirus viraemia | 41.74 | 34.56 | 10 | 3157 | 1152 | 64494413 |
Retinal artery occlusion | 41.36 | 34.56 | 12 | 3155 | 2891 | 64492674 |
Epstein-Barr virus infection | 40.14 | 34.56 | 17 | 3150 | 12471 | 64483094 |
Cytomegalovirus chorioretinitis | 39.10 | 34.56 | 13 | 3154 | 4899 | 64490666 |
Tonsil cancer | 38.33 | 34.56 | 9 | 3158 | 951 | 64494614 |
Complications of transplanted kidney | 37.81 | 34.56 | 13 | 3154 | 5422 | 64490143 |
Brain abscess | 37.05 | 34.56 | 12 | 3155 | 4169 | 64491396 |
Aspergillus infection | 35.71 | 34.56 | 17 | 3150 | 16362 | 64479203 |
None
Source | Code | Description |
---|---|---|
ATC | L04AA28 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Selective immunosuppressants |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D000074322 | Antineoplastic Agents, Immunological |
MeSH PA | D018501 | Antirheumatic Agents |
MeSH PA | D000082082 | Immune Checkpoint Inhibitors |
MeSH PA | D007155 | Immunologic Factors |
MeSH PA | D007166 | Immunosuppressive Agents |
FDA MoA | N0000182150 | CD80-directed Antibody Interactions |
FDA MoA | N0000182151 | CD86-directed Antibody Interactions |
FDA PE | N0000182829 | T Lymphocyte Costimulation Activity Blockade |
FDA EPC | N0000182830 | Selective T Cell Costimulation Blocker |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Renal transplant rejection | indication | 236570004 |
None
None
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
T-lymphocyte activation antigen CD80 | Surface antigen | INHIBITOR | DRUG LABEL | DRUG LABEL | |||||
T-lymphocyte activation antigen CD86 | Surface antigen | INHIBITOR | DRUG LABEL | DRUG LABEL |
ID | Source |
---|---|
E3B2GI648A | UNII |
D03222 | KEGG_DRUG |
4030905 | VANDF |
C1619962 | UMLSCUI |
CHEMBL1742990 | ChEMBL_ID |
DB06681 | DRUGBANK_ID |
D000069594 | MESH_DESCRIPTOR_UI |
8627 | INN_ID |
6892 | IUPHAR_LIGAND_ID |
1112973 | RXNORM |
183036 | MMSL |
27948 | MMSL |
d07787 | MMSL |
713475001 | SNOMEDCT_US |
714777004 | SNOMEDCT_US |
013827 | NDDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
NULOJIX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-0371 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 250 mg | INTRAVENOUS | BLA | 30 sections |